BRI-50460

CAT: 0804-HY-173371-01Size: 5 mgDry Ice: NoHazardous: No
CAT#:0804-HY-173371-01Size:5 mg
Selected
AVAILABILITY: InStock
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Product image 1
1 / 1
Description
BRI-50460 is an inhibitor of cytosolic calcium-dependent phospholipase A2 (cPLA2) that has the ability to penetrate the blood-brain barrier, with an IC50 of 0.88 nM. BRI-50460 exerts the activities of regulating neuroinflammation and restoring lipid homeostasis by inhibiting cPLA2, regulating the downstream inflammatory lipid signaling pathway, and alleviating the effects of amyloid β42 oligomers on the activation of cPLA2, the hyperphosphorylation of tau protein, and the reduction of synapses and dendrites. BRI-50460 can be applied to the research in the fields of Alzheimer's disease and other neurodegenerative diseases[1].
UNSPSC
12352005
Target
Phospholipase
Related Pathways
Metabolic Enzyme/Protease
Applications
Neuroscience-Neurodegeneration
Field of Research
Neurological Disease
Purity
99.62
Solubility
DMSO : 100 mg/mL (ultrasonic)
Smiles
O=C(CC1)NC2=C1C=CC(NS(C3=CC=CC(OC4=CC=CC=C4)=C3)(=O)=O)=C2
Molecular Formula
C21H18N2O4S
Molecular Weight
394.44
References & Citations
[1]Sadybekov A V, et al. Development of Potent, Selective cPLA2 Inhibitors for Targeting Neuroinflammation in Alzheimer's Disease and Other Neurodegenerative Disorders[J]. bioRxiv, 2025: 2025.03. 09.641748.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported

Popular Products